decisionhealth Newsletters, Coder Pink Sheets - 2009 Issue 4 (April)
FDA targets pain meds. . . again
Subscribe or sign in to view the full article.
Article Overview
This article covers an FDA announcement affecting commonly used opioid pain medications and the agency’s planned risk evaluation and mitigation process. It also discusses the billing and compliance context for opiate screening in physician offices, including lab certification and Medicare-related limitations. The piece is intended for pain management and coding/billing professionals who need to track regulatory changes and testing requirements.
Why This Topic Matters
It helps practices monitor federal drug-safety actions that may affect prescribing workflows, patient screening, and reimbursement compliance in pain management settings.
What You Will Learn
- What the FDA announced regarding opioid pain medications
- How the article frames the compliance issues around opiate screening in physician offices
- Why laboratory certification and Medicare-related requirements matter for testing
- What kinds of stakeholders are involved in the FDA review process
Who Should Read This
- Pain management physicians
- Anesthesia and pain coding professionals
- Medical billing and compliance staff
- Practice administrators
- Laboratory billing staff
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com